1
|
P S S, Trivedi RK, Srinivas NR, Mullangi R. A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices. Biomed Chromatogr 2019; 34:e4742. [PMID: 31749152 DOI: 10.1002/bmc.4742] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 10/24/2019] [Accepted: 10/30/2019] [Indexed: 12/31/2022]
Abstract
Quantitation of drugs used for the treatment of chronic lymphocytic leukemia in various biological matrices during both pre-clinical and clinical developments is very important, often in routine therapeutic drug monitoring. The first developed methods for quantitation were traditionally done on LC in combination with either UV or fluorescence detection. However, the emergence of LC with mass spectrometry in tandem in early 1990s has revolutionized the quantitation as it has provided better sensitivity and selectivity within a shorter run time; therefore it has become the choice of method for the analysis of various drugs. In this article, an overview of various bioanalytical methods (HPLC or LC-MS/MS) for the quantification of drugs for the treatment of chronic lymphocytic leukemia, along with applicability of these methods, is given.
Collapse
Affiliation(s)
- Suresh P S
- Jubilant Biosys, 2nd Stage, Bangalore, India
| | | | | | | |
Collapse
|
2
|
Hall OM, Peer CJ, Fitzhugh CD, Figg WD. A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1086:56-62. [PMID: 29656084 DOI: 10.1016/j.jchromb.2018.04.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 03/26/2018] [Accepted: 04/07/2018] [Indexed: 10/17/2022]
Abstract
Analysis of cyclophosphamide (CP) and its metabolite, 4-hydroxycyclophosphamide (4OHCP), in a single assay has the ability to improve sampling techniques benefitting both the patients who are receiving the drug and the clinicians drawing samples. Due to instability in plasma (t1/2 = 4 min), immediate stabilization of 4OHCP with phenylhydrazine is necessary upon sample draw. After stabilization, 4OHCP and the stable CP prodrug concentrations can be analytically measured to elucidate the pharmacokinetics, including half-life and exposure parameters (Cmax and AUC). For this purpose, a sensitive analytical method was developed to measure both the prodrug and active metabolite. A liquid-liquid extraction recovered the analytes prior to analysis with an ultra HPLC-MS/MS. A Thermo Scientific™ Hypersil™ BDS C18, 2.1 × 100 mm, 3.0 μm column was used for compound separation. Mass transitions for CP (m/z 261.0 ➔ 140.0), the internal standard d4-CP (m/z 265.0 ➔ 140.0), 4OHCP (m/z 367.3 ➔ 147.1), and the internal standard AZD7451 (m/z 383.4 ➔ 341.1) were monitored over a calibration range of 34.24-34,240 ng/mL and 3.424-3424 ng/mL for CP and 4OHCP, respectively. Each calibration range proved accurate (<15% deviation) and precise (<15% RSD) for the desired compound. Using this method, CP and 4OHCP plasma levels can be measured in clinical samples from patients receiving this therapy.
Collapse
Affiliation(s)
- O Morgan Hall
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States
| | - Cody J Peer
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States
| | - Courtney D Fitzhugh
- Sickle Cell Branch, National Heart, Lung and Blood Institute, Bethesda, MD, United States
| | - William D Figg
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States.
| |
Collapse
|
3
|
Yang L, Yan C, Zhang F, Jiang B, Gao S, Liang Y, Huang L, Chen W. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim 2017; 67:71-82. [PMID: 29129847 PMCID: PMC5814316 DOI: 10.1538/expanim.17-0048] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Cyclophosphamide (CP) is widely used in anticancer therapy regimens and 2-dechloroethylcyclophosphamide (DECP) is its side-chain dechloroethylated metabolite. N-dechloroethylation of CP mediated by the enzyme CYP3A4 yields nephrotoxic and neurotoxic chloroacetaldehyde (CAA) in equimolar amount to DECP. This study aimed to evaluate the inhibitory effect of ketoconazole (KTZ) on CP metabolism through in vitro and in vivo drug-drug interaction (DDI) research. Long-term treatment of KTZ induces hepatic injury; thus single doses of KTZ at low, middle, and high levels (10, 20, and 40 mg/kg) were investigated for pharmacokinetic DDI with CP. Our in vitro human liver microsome modeling approach suggested that KTZ inhibited CYP3A4 activity and then decreased DECP exposure. In addition, an UHPLC-MS/MS method for quantifying CP, DECP, and KTZ in rat plasma was developed and fully validated with a 4 min analysis coupled with a simple and reproducible one-step protein precipitation. A further in vivo pharmacokinetic study demonstrated that combination use of CP (10 mg/kg) and KTZ (10, 20, and 40 mg/kg) in rats caused a KTZ dose-dependent decrease in main parameters of DECP (Cmax, Tmax, and AUC0-∞) and provided magnitude exposure of DECP (more than a 50% AUC decrease) as a consequence of CYP3A inhibition but had only a small effect on the CP plasma concentration. Our results suggested that combination usage of a CYP3A4 inhibitor like KTZ may decrease CAA exposure and thus intervene against CAA-induced adverse effects in CP clinical treatment.
Collapse
Affiliation(s)
- Le Yang
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Chenyang Yan
- Department of Quality Management, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Feng Zhang
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Bo Jiang
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Shouhong Gao
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Youtian Liang
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Lifeng Huang
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| | - Wansheng Chen
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai 200003, P.R. China
| |
Collapse
|
4
|
Gong X, Yang L, Zhang F, Liang Y, Gao S, Liu K, Chen W. Validated UHPLC-MS/MS assay for quantitative determination of etoposide, gemcitabine, vinorelbine and their metabolites in patients with lung cancer. Biomed Chromatogr 2017; 31. [PMID: 28409868 DOI: 10.1002/bmc.3989] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2016] [Revised: 03/05/2017] [Accepted: 04/07/2017] [Indexed: 11/07/2022]
Affiliation(s)
- Xiaobin Gong
- Department of Pharmacy; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| | - Le Yang
- Department of Pharmacy; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| | - Feng Zhang
- Department of Pharmacy; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| | - Youtian Liang
- Department of Pharmacy; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| | - Shouhong Gao
- Department of Pharmacy; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| | - Ke Liu
- Department of Oncology; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| | - Wansheng Chen
- Department of Pharmacy; Changzheng Hospital, Second Military Medical University; Shanghai People's Republic of China
| |
Collapse
|
5
|
Guichard N, Guillarme D, Bonnabry P, Fleury-Souverain S. Antineoplastic drugs and their analysis: a state of the art review. Analyst 2017; 142:2273-2321. [DOI: 10.1039/c7an00367f] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We provide an overview of the analytical methods available for the quantification of antineoplastic drugs in pharmaceutical formulations, biological and environmental samples.
Collapse
Affiliation(s)
- Nicolas Guichard
- Pharmacy
- Geneva University Hospitals (HUG)
- Geneva
- Switzerland
- School of Pharmaceutical Sciences
| | - Davy Guillarme
- School of Pharmaceutical Sciences
- University of Geneva
- University of Lausanne
- Geneva
- Switzerland
| | - Pascal Bonnabry
- Pharmacy
- Geneva University Hospitals (HUG)
- Geneva
- Switzerland
- School of Pharmaceutical Sciences
| | | |
Collapse
|
6
|
Dal Bello F, Santoro V, Scarpino V, Martano C, Aigotti R, Chiappa A, Davoli E, Medana C. Antineoplastic drugs determination by HPLC-HRMS(n) to monitor occupational exposure. Drug Test Anal 2015; 8:730-7. [PMID: 26041114 DOI: 10.1002/dta.1827] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Revised: 05/21/2015] [Accepted: 05/21/2015] [Indexed: 11/07/2022]
Abstract
The purpose of this study was to develop a simple, direct, multiresidue highly specific procedure to evaluate the possible surface contamination of selected antineoplastic drugs in several hospital environment sites by using wipe test sampling. 5-fluorouracil (5-FU), carboplatin (C-Pt), cyclophosphamide (CYC), cytarabine (CYT), doxorubicin (DOX), gemcitabine (GEM), ifosfamide (IFO), methotrexate (MET), and mitomycin C (MIT) belong to very different chemical classes but show good ionization properties under electrospray ionization (ESI) conditions (negative ion mode for 5-FU and positive ion mode in all other cases). HPLC (high performance liquid chromatography) coupled with HRMS (high resolution mass spectrometry) appears to be the best technique for direct analysis of these analytes, because neither derivatization nor complex extraction procedure for polar compounds in samples is requested prior the analysis. Sample preparation was limited to washing wipes with appropriate solvents. Chromatographic separation was achieved on C18 reversed phase columns. The HPLC-HRMS/MS method was validated in order to obtain robustness, sensitivity and selectivity. LLOQ (lower limit of quantitation) values provided a sensitivity good enough to evidence the presence of the drugs in a very low concentration range (<1 pg/cm(2) ). The method was applied for a study of real wipe tests coming from many areas from a hospital showing some positive samples. The low quantitation limits and the high specificity due to the high resolution approach of the developed method allowed an accurate description of the working environment that can be used to define procedural rules to limit working place contamination to a minimum. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Federica Dal Bello
- Molecular Biotechnology and Health Sciences Department, University of Turin, Via P. Giuria 5, 10125, Turin, Italy
| | - Valentina Santoro
- Molecular Biotechnology and Health Sciences Department, University of Turin, Via P. Giuria 5, 10125, Turin, Italy
| | - Valentina Scarpino
- Molecular Biotechnology and Health Sciences Department, University of Turin, Via P. Giuria 5, 10125, Turin, Italy
| | - Chiara Martano
- Molecular Biotechnology and Health Sciences Department, University of Turin, Via P. Giuria 5, 10125, Turin, Italy
| | - Riccardo Aigotti
- Molecular Biotechnology and Health Sciences Department, University of Turin, Via P. Giuria 5, 10125, Turin, Italy
| | - Alberta Chiappa
- Servizio Idrico Milanese, Metropolitana Milanese, Via del Vecchio Politecnico 8, 20121, Milano, Italy
| | - Enrico Davoli
- Mass Spectrometry Laboratory, Environmental Health Sciences Department, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Via La Masa 19, 20156, Milano, Italy
| | - Claudio Medana
- Molecular Biotechnology and Health Sciences Department, University of Turin, Via P. Giuria 5, 10125, Turin, Italy
| |
Collapse
|